

Clinical Policy: Insulin Glargine (Basaglar, Langlara, Lantus/unbranded Lantus, Rezvoglar, Toujeo/unbranded Toujeo)

Reference Number: HIM.PA.09

Effective Date: 03.01.19

Last Review Date: 12.25

Line of Business: HIM

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Insulin glargine (Basaglar[®], Langlara[™], Lantus[®]/unbranded Lantus[®], Rezvoglar[™], Toujeo[®]/unbranded Toujeo[®]) is a long-acting human insulin analog.

FDA Approved Indication(s)

Basaglar is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Langlara, Lantus/unbranded Lantus, and Rezvoglar are indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Toujeo/unbranded Toujeo is indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

Limitation(s) of use: Basaglar, Langlara, Lantus/unbranded Lantus, Toujeo/unbranded Toujeo, and Rezvoglar are not recommended for treating diabetic ketoacidosis.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Basaglar, Langlara, Lantus/unbranded Lantus, Rezvoglar, and Toujeo/unbranded Toujeo are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Diabetes Mellitus (must meet all):

1. Diagnosis of type 1 or type 2 diabetes mellitus;
2. Both of the following (a and b), unless clinically significant adverse effects are experienced or both are contraindicated:*

**For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395*

- a. Member must use insulin glargine-yfgn (unbranded Semglee[®]);
- b. Failure of branded Tresiba[®] (insulin degludec).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace.

II. Continued Therapy

A. Diabetes Mellitus (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Both of the following (a and b), unless clinically significant adverse effects are experienced or both are contraindicated:*^
**For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395*
^For New York requests, the step therapy requirements below do not apply
 - a. Member must use insulin glargine-yfgn (unbranded Semglee);
 - b. Failure of branded Tresiba (insulin degludec);
3. Member is responding positively to therapy.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PA.154 for health insurance marketplace or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
insulin degludec (branded Tresiba)	<p>Type 1 diabetes mellitus: Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 1/3 to 1/2 of total daily insulin dose SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Adults: same unit dose as total daily long or intermediate-acting insulin unit dose ○ Pediatrics: 80% of total daily long or intermediate-acting insulin unit dose <p>Type 2 diabetes mellitus: Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 10 units SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Adults: same unit dose as total daily long or intermediate-acting insulin unit dose ○ Pediatrics: 80% of total daily long or intermediate-acting insulin unit dose 	Not applicable
insulin glargine-yfqn (Semglee)	<p>Type 1 diabetes mellitus: Initiation:</p> <ul style="list-style-type: none"> • Approximately one-third of the total daily insulin requirement administered SC QD <p>Type 2 diabetes mellitus: Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 0.2 units/kg SC QD or up to 10 units/day. Adjust dosage according to patient response 	Not applicable

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): use during episodes of hypoglycemia, hypersensitivity to the requested product or one of its excipients

- Boxed warning(s): none reported

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Insulin glargine (Toujeo/ unbranded Toujeo)	Type 1 diabetes mellitus	<p>Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 1/3 to 1/2 of total daily insulin dose SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Once-daily long or intermediate insulin: same unit dose as total daily long acting insulin unit dose. Expect higher daily dose of Toujeo will be needed to maintain the same level of glycemic control in patients on Lantus. ○ Twice-daily long or intermediate insulin: 80% of total daily long or intermediate-acting insulin unit dose 	Not applicable; dose is individualized and titrated based on metabolic needs, blood glucose monitoring results, and glycemic control goal
	Type 2 diabetes mellitus	<p>Initiation:</p> <ul style="list-style-type: none"> • Insulin-naïve: 0.2 units/kg SC QD • Already on insulin: SC QD: <ul style="list-style-type: none"> ○ Once-daily long or intermediate insulin: same unit dose as total daily long acting insulin unit dose. Expect higher daily dose of Toujeo will be needed to maintain the same level of glycemic control in patients on Lantus. ○ Twice-daily long or intermediate insulin: 80% of total daily long or intermediate-acting insulin unit dose 	Not applicable; dose is individualized and titrated based on metabolic needs, blood glucose monitoring results, and glycemic control goal
Insulin glargine (Basaglar), insulin glargine-aldy (Langlara), insulin glargine (Lantus/ unbranded Lantus),	Type 1 diabetes mellitus	Initiation: Approximately one-third of the total daily insulin requirement administered SC QD	Not applicable
	Type 2 diabetes mellitus	Initiation: 0.2 units/kg SC QD or up to 10 units/day. Adjust dosage according to patient response	Not applicable

Drug Name	Indication	Dosing Regimen	Maximum Dose
insulin glargine-aglr (Rezvoglar)			

VI. Product Availability

Drug Name	Availability
Insulin glargine (Basaglar)	Single-patient-use prefilled pen 100 units/mL: 3 mL (Basaglar KwikPen [®] , Basaglar Tempo Pen [™])
Insulin glargine (Lantus/unbranded Lantus)	Multiple-dose vial: 10 mL containing 100 units/mL Single-patient-use prefilled pen (Lantus SoloStar): 3 mL containing 100 units/mL
Insulin glargine-aldy (Langlara)	Single-patient-use prefilled pen: 3 mL containing 100 units/mL
Insulin glargine (Toujeo/unbranded Toujeo)	Single-patient-use prefilled pen 300 units/mL: 1.5 mL (Toujeo SoloStar), 3 mL (Toujeo Max SoloStar)
Insulin glargine-aglr (Rezvoglar)	KwikPen [®] prefilled pen: 3 mL containing 100 units/mL

VII. References

1. Toujeo Prescribing Information. Bridgewater, NJ: Sanofi Aventis U.S. LLC; May 2025. Available at: www.toujeo.com. Accessed July 16, 2025.
2. Rezvoglar Prescribing Information. Indianapolis, IN: Eli Lilly and Company; August 2024. Available at: <https://uspl.lilly.com/rezvoglar/rezvoglar.html#pi>. Accessed July 16, 2025.
3. Basaglar Prescribing Information. Indianapolis, IN; Eli Lilly and Company; November 2023. Available at: <https://uspl.lilly.com/basaglar/basaglar.html#pi>. Accessed July 16, 2025.
4. Lantus Prescribing Information. Bridgewater, NJ: Sanofi Aventis U.S. LLC; June 2023. Available at: <https://products.sanofi.us/lantus/lantus.pdf>. Accessed July 16, 2025.
5. Langlara Prescriber Information. Philadelphia, PA: Lannett Company Inc.; April 2026. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761412Orig1s000lbl.pdf. Accessed May 6, 2026.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	10.26.20	02.21
Per October SDC and prior clinical guidance, removed Tresiba from policy as PA is no longer required; added Toujeo to policy and revised redirection to require use of Basaglar, Levemir, and Tresiba; revised required age to 6 years or older consistent with Semglee and Toujeo prescribing information.	10.27.21	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: RT4: added Rezvoglar to policy; references reviewed and updated.	01.10.22	02.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.11.22	
1Q 2023 annual review: no significant changes; RT4: updated FDA approved indications for Rezvolar to include pediatric extension in type 2 diabetes mellitus; references reviewed and updated.	10.27.22	02.23
Per August SDC, removed Levemir redirection and clarified redirection to unbranded Tresiba with references to preferred insulin degludec NDCs.	08.22.23	12.23
1Q 2024 annual review: for Semglee, updated FDA approved indications section to align with prescriber information; references reviewed and updated.	01.29.24	02.24
4Q 2024 annual review: removed age restriction to align with class approach for other insulin products; references reviewed and updated.	07.30.24	11.24
Per August SDC, removed Basaglar redirection and added redirection to branded Semglee; for Appendix B, added Semglee as therapeutic alternative option; added Basaglar to criteria; for continued therapy requests, added redirection to preferred products; added Insulin Glargine-yfgn to policy and clarified that criteria apply to unbranded Semglee.	08.22.24	12.24
Per SDC, added Lantus, unbranded Lantus, and unbranded Toujeo to criteria; updated redirection language from “failure of branded Semglee and unbranded Tresiba” to “member must use branded Semglee” and “failure of unbranded Tresiba” to align with biosimilar redirection language.	12.18.24	
Per SDC, removed unbranded Semglee from policy; added redirection to unbranded Semglee if branded Semglee is unavailable due to shortage.	07.10.25	
4Q 2025 annual review: added step therapy bypass for IL HIM per IL HB 5395; references reviewed and updated.	07.17.25	11.25
Per August SDC, removed redirection to branded Semglee and unbranded Tresiba from policy; added redirection to insulin glargine-yfgn (unbranded Semglee) and branded Tresiba.	08.20.25	12.25
RT4: added Langlara to policy.	05.06.26	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical

policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or

CLINICAL POLICY
Insulin Glargine



remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.